Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Primary liver cancer, hepatocellular carcinoma (HCC), is a leading cause of cancer death globally.
• Current therapeutic options for HCC are limited, necessitating novel treatment strategies.
• Granulin-epithelin precursor (GEP) has been identified as a potential therapeutic target for HCC.

Purpose of the Study:

• To investigate the therapeutic potential of an anti-GEP monoclonal antibody (mAb) against HCC.
• To evaluate the efficacy and safety of anti-GEP mAb in vitro and in vivo.

Main Methods:

• Development of an anti-GEP mAb.
• In vitro assessment of anti-GEP mAb effects on hepatoma and normal liver cells.
• In vivo evaluation of anti-GEP mAb in a human HCC xenograft nude mouse model.

Main Results:

• Anti-GEP mAb inhibited hepatoma cell growth in vitro with no significant effect on normal liver cells.
• In vivo, anti-GEP mAb reduced serum GEP levels and dose-dependently inhibited established HCC tumor growth.
• The antibody suppressed tumor cell proliferation via MAPK and Akt pathways and reduced tumor angiogenesis.

Conclusions:

• Anti-GEP antibody demonstrates significant efficacy in inhibiting HCC growth.
• GEP is validated as a promising therapeutic target for HCC treatment.